Hereditary Angioedema Treatment Market: By Product (Kalbitor, Ruconest, Icatibant, Firazyre, Berinert, Orladeyo, Cinryze, Haegarda and Takhzyro), By Drug Class (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor and Others) By Route of Administration (Intravenous, Subcutaneous and Oral) and Geography (North America, Europe, Asia Pacific, Latin America and MEA) and forecast to 2029

Hereditary Angioedema Treatment Market Regional Analysis

North America Got Significant Share

In Asia-Pacific, for Japan, the drugs which are approved for HAE treatment are Berinert, Icatibant, Firazyr and Orladeyo. In Australia, the following drugs Cinryze, Berinert, Haegarda, Icatibant (Firazyr), Lanadelumab, and Takhzyro are available for HAE treatment. In India, Berinert, Cinryze, Haegarda, Ruconest, Icatibant, Ecallantide (Kalbitor), Lanadelumab and Berotralstat are available for treatment of HAE. However, The mortality from HAE has dramatically decreased as a result of the availability of contemporary therapeutic options in several nations. Fresh frozen plasma, attenuated androgens, and tranexamic acid are used to treat HAE patients in the majority of underdeveloped nations, as all first-line treatment alternatives are currently unavailable. However, individuals with HAE in developing countries will soon have access to additional cutting-edge treatment choices due to continuous efforts from patient groups and the medical community.